摘要
目的:探究哌拉西林舒巴坦与孟鲁司特联合治疗慢性阻塞性肺疾患者的临床效果。方法:选取2016年6月-2018年6月本院收治的360例慢性阻塞性肺疾病患者,依据随机数字表法将其分为对照组和观察组,每组180例。两组采用相同的治疗手段进行常规治疗,在此基础上,对照组予以哌拉西林舒巴坦治疗,观察组予以哌拉西林舒巴坦与孟鲁司特联合治疗。比较两组的临床疗效、临床症状及肺功能的改变情况。结果:治疗后,观察组的FEV1、FVC、FEV1/FVC%、PaO2以及SaO2均显著高于对照组,PaCO2低于对照组,差异均有统计学意义(P<0.05)。治疗后,观察组的呼吸困难、咳嗽、咳痰、喘息以及胸闷评分均显著低于对照组,差异均有统计学意义(P<0.05)。观察组治疗总有效率为98.33%,显著高于对照组的91.67%,差异有统计学意义(P<0.05)。结论:在对慢性阻塞性肺疾病患者的治疗中,为取得良好的临床疗效,可在常规治疗的基础上应用哌拉西林舒巴坦与孟鲁司特联合治疗,可显著改善临床症状,临床疗效显著,临床价值重大。
Objective:To investigate the clinical effect of Piperacillin Sulbactam combined with Montelukast in the treatment of chronic obstructive pulmonary disease patients.Method:A total of 360 patients with chronic obstructive pulmonary disease admitted to our hospital from June 2016 to June 2018 were selected.According to the random number table method,they were divided into control group and observation group,180 cases in each group.The two groups received the same treatment methods for routine treatment,on this basis,the control group received Piperacillin Sulbactam treatment,and the observation group received Piperacillin Sulbactam combined with Montelukast treatment.The clinical efficacy,clinical symptoms and pulmonary function changes of the two groups were compared.Result:After treatment,FEV1,FVC,FEV1/FVC%,PaO2 and SaO2 in the observation group were significantly higher than those in the control group,PaCO2 was lower than the control group,the differences were statistically significant(P<0.05).After treatment,scores of dyspnea,cough,expectoration,wheezing and chest distress in the observation group were significantly lower than those in the control group,the differences were statistically significant(P<0.05).The total effective rate of the observation group was 98.33%,significantly higher than the 91.67%in the control group,the difference was statistically significant(P<0.05).Conclusion:In the treatment of patients with chronic obstructive pulmonary disease,in order to achieve good clinical efficacy,Piperacillin Sulbactam combined with Montelukast can be used on the basis of conventional treatment,which can significantly improve the clinical symptoms,clinical efficacy is significant,and clinical value is significant.
作者
李芳芳
LI Fangfang(Shunyi District Maternal and Child Health Hospital of Beijing(Shunyi Maternal and Child Hospital of Beijing Children's Hospital),Beijing 101300,China)
出处
《中国医学创新》
CAS
2020年第12期43-46,共4页
Medical Innovation of China
基金
首都卫生发展科研专项基金(2016-4024-05)。
关键词
哌拉西林舒巴坦
孟鲁司特
慢性阻塞性肺疾病
肺功能
Piperacillin Sulbactam
Montelukast
Chronic obstructive pulmonary disease
Lung function
